Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature
about
Bacteriophage-derived vectors for targeted cancer gene therapyMan's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathwayProspective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsA Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer ModelIgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachGermline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patientsCombinatorial peptide libraries: mining for cell-binding peptides.Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant MelanomaTargeting TNF-alpha for cancer therapy.Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogsRecent clinical trials of cancer immunogene therapy in companion animals.Targeting of drugs and nanoparticles to tumors.Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.Toward a drug development path that targets metastatic progression in osteosarcoma.Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphomaArterial embolization hyperthermia using As2O3 nanoparticles in VX2 carcinoma-induced liver tumors.Ligand-directed profiling of organelles with internalizing phage libraries.Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectorsLigand-targeted theranostic nanomedicines against cancerEvidence of an oncogenic gammaherpesvirus in domestic dogs.Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activityProteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.Peripheral blood biomarkers of solid tumor angiogenesis in dogs: a polychromatic flow cytometry pilot study.Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumorsAAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.Defining the Value of a Comparative Approach to Cancer Drug Development.Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.Cancer and comparative imaging.Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.Phage Therapy in the Era of Synthetic Biology.Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells.Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.An AAVP-based solid-phase transducing matrix for transgene delivery: potential for translational applications.Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage.
P2860
Q26865726-63E8F448-7D3B-4526-91C5-9CBA2E6FB366Q27027137-51FB69B4-5428-432C-B28A-57142DD7624AQ28476288-A733A609-AC81-47B7-962D-DAD6BFC9009AQ28540955-25A9C6F9-5FF1-4AB8-9D69-347A36AF16E0Q28550119-91764CF1-A930-4CA3-9629-853E3C069591Q28655505-B90C3513-B714-402A-B6DF-786B3DBAE78DQ30235105-A1DC14C4-5313-42A5-BEEB-C42F42E05D76Q30692995-BF7FE8C0-B3F5-4712-BAFF-51499E135861Q31144876-0C5B93F4-2981-4AB9-9B9D-3E42F2996A61Q33423772-620B5ABA-4ED7-4167-AD60-9E8F86B02D54Q33513307-840DEDE6-01D9-46C1-870F-A756D22FFB1AQ33603032-63E51E70-6582-43FA-85FD-9824706A44E0Q33711518-EA3472F3-3677-47BC-8C7D-0C266A4F9F6CQ33751710-7D6630FC-9307-4A19-B760-F54A660751B8Q33855456-3623C619-198D-4A42-A3D4-9729FFE3D425Q34052760-5F038C4C-3319-4B52-8495-F541AE54BC2AQ34168530-01446D67-DB5C-48F2-AC79-CAD7472D5708Q34373001-0692B84D-D1CB-434D-84CE-B6FCB4D06C71Q34712590-3F5324C5-363E-490E-B8CE-98C06820A925Q35553061-4DFB5A47-1864-49FA-A208-974BADB12E46Q35672938-6583EFB3-5D45-45AE-82B8-91220A3DDAD4Q35895637-1DE95F03-84C6-40C9-BEEC-C17A25A0D179Q36119183-CF63FF3E-2DC3-431D-A586-6113D1535E19Q36499644-207E6F5A-6142-4B34-9055-F149C24B9647Q36558030-D57FF113-3733-4FE0-BCC4-A068E360930CQ36605109-19685A5E-18BC-4612-B8FB-41D25E80F9B9Q36646454-3A78E4C1-7978-43AF-9C1C-495C20B3E281Q36659064-CAC1E3F4-CA17-41CA-BB95-E1BB338C88C7Q37417714-2DD8A3F3-8E03-4837-859F-D7029AB8BE74Q37417870-73764F9C-BC86-4285-A1FD-729F9F3506D3Q37417906-E409616B-9611-491E-9C49-3E8638A3713DQ37588421-F17431F0-0EFC-470D-8B1E-C8EBFEB47F4FQ38220808-C4DC63EA-07C8-4C8D-BE10-1191BBCA6DB4Q38265614-10A066B9-A15D-4022-B3E9-DC5F7D2E8960Q38834470-5CCBA571-C40B-4344-8543-32AC54758C76Q38915649-EDCC13AC-DD47-4AAF-B778-665FCBEDE623Q39072488-17C2A885-FB57-4C88-91CA-0AD65A94660DQ39237394-C942488D-D279-4759-927C-E864E5990863Q40184254-A5B81F2A-9CF1-4F73-B9BC-EB990300E1F2Q41960718-E76717ED-4D7D-4348-91E7-E6DDEED1BB2B
P2860
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@ast
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@en
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@nl
type
label
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@ast
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@en
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@nl
prefLabel
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@ast
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@en
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@nl
P2093
P2860
P50
P3181
P1433
P1476
Launching a novel preclinical ...... TNFalpha to cancer vasculature
@en
P2093
Amy Leblanc
Anita Tandle
Carolyn Henry
Chand Khanna
Christina Mazcko
David Vail
Engy Hanna
Karin Sorenmo
Melissa C Paoloni
Renata Pasqualini
P2860
P3181
P356
10.1371/JOURNAL.PONE.0004972
P407
P577
2009-03-30T00:00:00Z